AngioDynamics, Inc. (NASDAQ:ANGO) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC trimmed its position in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 13.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 913,029 shares of the medical instruments supplier's stock after selling 143,785 shares during the period. Renaissance Technologies LLC owned about 2.26% of AngioDynamics worth $8,363,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Rhumbline Advisers lifted its stake in AngioDynamics by 1.7% in the 4th quarter. Rhumbline Advisers now owns 60,479 shares of the medical instruments supplier's stock worth $554,000 after purchasing an additional 1,021 shares in the last quarter. Invesco Ltd. lifted its stake in AngioDynamics by 1.2% in the 4th quarter. Invesco Ltd. now owns 119,249 shares of the medical instruments supplier's stock worth $1,092,000 after purchasing an additional 1,451 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in AngioDynamics by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 329,090 shares of the medical instruments supplier's stock worth $3,014,000 after purchasing an additional 2,270 shares in the last quarter. SG Americas Securities LLC lifted its stake in AngioDynamics by 21.3% in the 4th quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier's stock worth $147,000 after purchasing an additional 2,832 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in AngioDynamics in the 4th quarter worth approximately $28,000. 89.43% of the stock is currently owned by institutional investors and hedge funds.

AngioDynamics Price Performance

Shares of ANGO stock traded up $0.33 during trading on Wednesday, hitting $9.63. 57,271 shares of the stock traded hands, compared to its average volume of 559,950. The firm has a market capitalization of $391.05 million, a P/E ratio of -1.71 and a beta of 0.52. The firm's fifty day moving average price is $9.61 and its 200-day moving average price is $9.06. AngioDynamics, Inc. has a 52-week low of $5.47 and a 52-week high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its quarterly earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.13) by $0.16. The firm had revenue of $72.00 million for the quarter, compared to analyst estimates of $70.30 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business's revenue was down 4.3% on a year-over-year basis. As a group, equities research analysts expect that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a "buy" rating and issued a $16.00 target price (up from $15.00) on shares of AngioDynamics in a research note on Monday, April 7th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.